Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration. 1986

L T Sennello, and R A Finley, and S Y Chu, and C Jagst, and D Max, and D E Rollins, and K G Tolman

A group of six normal adult male volunteers was divided into two groups (I and II) who received bolus intravenous and subcutaneous 1-mg doses of leuprolide. The study was of a randomized, complete-crossover design. Blood was collected from 0 to 48 h postdosing, and plasma was analyzed for leuprolide using a radioimmunoassay procedure. The data from the intravenous doses were fitted to a two-compartment open model with elimination from the central compartment, assuming a bolus (instantaneous) injection. The data from the subcutaneous doses were fitted to a two-compartment open model with elimination from the central compartment and first-order (monoexponential) absorption from the injection site. Statistical moments were also calculated for both sets of data. The mean beta half-life after the intravenous dosings was 2.9 h and after the subcutaneous dosings was 3.6 h. The difference between these two values, as well as those for plasma clearance, variance in residence time, and volume of distribution at steady state was not statistically significant; however, the differences between the mean values of k21, k12, kel, apparent volume of distribution of the central compartment, mean residence time, and area under the moment curve for the routes of administration were significant (p less than 0.05). The mean residence time following the intravenous dosings averaged 3.1 h and following the subcutaneous dosings averaged 4.3 h, indicating an average mean residence time at the subcutaneous injection site of 1.2 h. The mean volume of distribution at steady state from the intravenous and subcutaneous doses were 26.5 and 37.1 L, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D007700 Kinetics The rate dynamics in chemical or physical systems.
D007987 Gonadotropin-Releasing Hormone A decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. GnRH is produced by neurons in the septum PREOPTIC AREA of the HYPOTHALAMUS and released into the pituitary portal blood, leading to stimulation of GONADOTROPHS in the ANTERIOR PITUITARY GLAND. FSH-Releasing Hormone,GnRH,Gonadoliberin,Gonadorelin,LH-FSH Releasing Hormone,LHRH,Luliberin,Luteinizing Hormone-Releasing Hormone,Cystorelin,Dirigestran,Factrel,Gn-RH,Gonadorelin Acetate,Gonadorelin Hydrochloride,Kryptocur,LFRH,LH-RH,LH-Releasing Hormone,LHFSH Releasing Hormone,LHFSHRH,FSH Releasing Hormone,Gonadotropin Releasing Hormone,LH FSH Releasing Hormone,LH Releasing Hormone,Luteinizing Hormone Releasing Hormone,Releasing Hormone, LHFSH
D008297 Male Males
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D016729 Leuprolide A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. Leuprorelin,A-43818,Enantone,Leuprolide Acetate,Leuprolide Monoacetate,Leuprolide, (DL-Leu)-Isomer,Leuprolide, (L-Leu)-Isomer,Lupron,TAP-144,A 43818,A43818,Acetate, Leuprolide,Monoacetate, Leuprolide,TAP 144,TAP144

Related Publications

L T Sennello, and R A Finley, and S Y Chu, and C Jagst, and D Max, and D E Rollins, and K G Tolman
January 1980, Clinical therapeutics,
L T Sennello, and R A Finley, and S Y Chu, and C Jagst, and D Max, and D E Rollins, and K G Tolman
January 1996, Biology of the neonate,
L T Sennello, and R A Finley, and S Y Chu, and C Jagst, and D Max, and D E Rollins, and K G Tolman
January 1985, International journal of clinical pharmacology, therapy, and toxicology,
L T Sennello, and R A Finley, and S Y Chu, and C Jagst, and D Max, and D E Rollins, and K G Tolman
January 2000, American journal of veterinary research,
L T Sennello, and R A Finley, and S Y Chu, and C Jagst, and D Max, and D E Rollins, and K G Tolman
August 2006, Journal of veterinary pharmacology and therapeutics,
L T Sennello, and R A Finley, and S Y Chu, and C Jagst, and D Max, and D E Rollins, and K G Tolman
January 1986, Biopharmaceutics & drug disposition,
L T Sennello, and R A Finley, and S Y Chu, and C Jagst, and D Max, and D E Rollins, and K G Tolman
April 1993, The Journal of pediatrics,
L T Sennello, and R A Finley, and S Y Chu, and C Jagst, and D Max, and D E Rollins, and K G Tolman
October 1994, Journal of veterinary pharmacology and therapeutics,
L T Sennello, and R A Finley, and S Y Chu, and C Jagst, and D Max, and D E Rollins, and K G Tolman
November 2022, Journal of veterinary pharmacology and therapeutics,
L T Sennello, and R A Finley, and S Y Chu, and C Jagst, and D Max, and D E Rollins, and K G Tolman
March 1986, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!